Dose reduction of L-carnitine and serum carnitine concentration in hemodialysis patients

Dose reduction of L-carnitine and serum carnitine concentration in hemodialysis patients - Reduction of L-carnitine and concentration in HD patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000037330

Enrollment

Registered

2019-07-10

Start date

2019-07-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure

Interventions

L-carnitine 1000mg 3 times/week for 6 months L-carnitine 1000mg 1 time/week + salone 2 times/week for 6 months saline 3 times/week for 6 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HD patients At least 3 months L-carnitine 1000mg 3times/week treatment Patients who have stable Patients whose Hb levels above 10g/dL

Exclusion criteria

Exclusion criteria: Symptoms are not stable. Hb levels below 10g/dl

Design outcomes

Primary

Measure	Time frame
Serum carnitine levels	—

Secondary

Measure	Time frame
ERI, prevalence of clamp and fatigue, inflammation, oxidative stress, skin AGE levels, LVMI, EKG changes	—

Countries

Japan

Contacts

Public ContactKei Fukami

Kurume University School of Medicine Division of Nephrology, Department of Medicine

fukami@med.kurume-u.ac.jp0942353311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026